A number of reports indicating that hepcidin is competent to distinguish between IDA and AI in several diseases, including RA, anemia of cancer, anemia of critical illness, and IBD, have suggested hepcidin to be a promising biomarker in the future [16,80,81,82,83]. The gene discussed is HAMP; the disease is anemia.